CJC-1295 vs Pal-GHK
Side-by-side comparison of key properties, dosing, and research.
- Summary
- CJC-1295 is a synthetic GHRH analog that stimulates the pituitary gland to produce and release growth hormone. The DAC (Drug Affinity Complex) version has a markedly extended half-life. The No DAC version (Modified GRF 1-29) preserves natural pulsatile GH release and is preferred in most protocols.
- Pal-GHK is the palmitoylated form of the GHK tripeptide without a copper ion. By conjugating palmitic acid to glycine-histidine-lysine, skin penetration is substantially enhanced, enabling deeper dermal collagen stimulation. It is commonly paired with Pal-GHK-Cu or GHK-Cu in anti-aging formulations.
- Half-Life
- ~30 minutes (No DAC) / 6–8 days (with DAC)
- Extended (lipid depot in stratum corneum)
- Admin Route
- SubQ
- Topical
- Research
- —
- —
- Typical Dose
- 100 mcg
- 0.005–0.1% in formulation
- Frequency
- Once daily, before bed
- Once or twice daily
- Key Benefits
- Sustained increase in growth hormone levels
- Enhanced muscle growth and strength
- Improved fat metabolism and body composition
- Better recovery and tissue repair
- Increased bone density
- Enhanced immune function
- Improved skin quality and collagen production
- Synergistic GH release when combined with GHRPs like Ipamorelin
- Stimulates collagen I and III synthesis in dermis
- Reduces the appearance of fine lines and wrinkles
- Improves skin elasticity and firmness
- Inhibits collagenase (MMP-1) to preserve existing collagen
- Enhances wound healing and skin repair
- Well-tolerated in anti-aging serums and creams
- Side Effects
- Water retention / puffiness
- Carpal tunnel syndrome (with prolonged use)
- Injection site irritation
- Hunger increase (minor)
- +1 more
- Generally very well-tolerated
- Rare skin irritation at very high concentrations
- Possible formulation-dependent comedogenicity
- Stacks With
- —
- —